相关实验视频

Updated: Feb 17, 2026

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

特定亚型的Sirtuin表达特征将线粒体-表观遗传网络与乳腺癌存活率联系起来

Zoltan Ungvari^1,2, Otília Menyhárt^3,4,5, Alberto Ocana^6,7

¹Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

|February 15, 2026

概括

赛尔图因 (静音交配类型信息调节2同类物) 是衰老和乳腺癌的关键调节剂. 多基因sirtuin面板有效预测乳腺癌亚型的无复发生存率,揭示了治疗脆弱性.

科学领域:

生物化学和分子生物学
遗传学和基因组学遗传学和基因组学
在瘤学瘤学.

背景情况:

赛尔图因 (静态交配类型信息调节2同类,SIRT1-SIRT7) 是NAD+依赖的酶,参与衰老和癌症.
乳腺癌 (BC) 是一种异质性疾病,其中素在代谢和表观遗传学中发挥作用.

研究的目的:

系统地评估乳腺癌分子亚型中sirtuins的预后价值和转录模式.
在乳腺癌患者中确定多基因sirtuin签名来预测无复发生存率 (RFS).

主要方法:

来自55个乳腺癌数据集 (n=4384) 的基因表达和生存数据的综合分析.
单个sirtuins和多基因组合的单变Cox和Kaplan-Meier分析.
使用TNMplot平台进行差异表达和协同表达分析.

主要成果:

在PAM50亚型中,SIRT3显示出与改善RFS的最一致的关联.
多基因sirtuin面板显著优于单个基因,显示亚型特异性.
一个三基因小组 (SIRT3+SIRT5+SIRT6) 和一个SIRT3+SIRT6+SIRT7小组在各种BC亚型中有效地分层风险.

结论:

赛尔图因签名在乳腺癌亚型中提供了强大的RFS分层.
这些发现突出了sirtuins作为长寿和瘤代谢的整合者,表明潜在的治疗点.
协同作用,sirtuins的上下文依赖的影响表明NAD + 依赖的调节通路中的可利用的漏洞.

关键词:

衰老癌症的界面接口老龄化与癌症的关系乳腺癌是什么? 乳腺癌是什么?同表达网络的共同表达.表观遗传调节,子类型特定的签名.妇科癌症学妇科癌症学长寿基因是一种长寿基因.线粒体信号传递多基因签名多基因签名 NAD+代谢 NAD+的代谢预测模型是一个预测模型.没有复发的生存率.塞尔图因斯是什么意思转录组合的整合

更多相关视频

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...